Health 2.0 Europe 2011 is Accepting Speaker Submissions

Following the success of the first event in Paris in April 2010, the 2nd annual Health 2.0 Europe will showcase the best of Europe's user-generated healthcare and reconvene over 500 leaders and stakeholders in Web 2.0 for health. Participants will include IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical device and pharmaceutical companies, telecom groups, VC and financiers, policy makers, and academics.

If you are in the Health 2.0 space and offer a technology or service that is particularly innovative or provides a solution to a major healthcare challenge, Health 2.0 wants to hear from you! In general, most of the programming consists of panels with speakers showing their technology in 4-minute demos, and commentators reflecting on what they hear and how it will fit into healthcare from their perspective, followed by interaction with the demonstrators.

Themes for 2011 will include:

  • Patient and physician social networks
  • Search & content
  • Communities and data production
  • Consumer and provider tools
  • Health promotion, behavior change and Wellness 2.0
  • Data utility layer & tools
  • System integration
  • Health 2.0 financing
  • Cloud computing and unplatforms

More information on the programme is available at http://www.health2con.com/europe/.

Decisions on panelists are made by the organizers in close consultation with our Advisory Board. It is a highly selective process as the topic of the conference, audience interest, diversity of presenters and format of panels are taken into consideration.

Apply now!

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...